Pharmaceutical Deal Trends 2017 Factbook

Pharmaceutical Deal Trends 2017 Factbook: Partnerships and Acquisitions Shift Focus Towards Early Stage Development, Emerging Markets, and Biologics

Recent studies shows, internally developed pipeline productivity at big pharma companies has decreased significantly, averaging only about one new molecular entity a year per company. Taking discontinued programs into account, the cost of bringing a new drug to market has continued to rise and is estimated to exceed $1 billion. Therefore, the traditional business model cannot be fruitful in the new market landscape.

Although the pharmaceutical market is continuing to see global growth, pharmaceutical and biotechnology companies are facing challenges due to disruptive events in the healthcare market such as increasing costs of production and R&D, shifts in patent laws, and challenges in the economy.

Factors Promoting Deal Activity

Key take-outs

  • Companies are considering various strategies to overcome the current challenges, with deal making being foremost among these as a means of boosting revenues over a short period of time.
  • Agreements between companies for drug discovery, which allow them to share the risk of co-developing products, have become more common.
  • Small companies that primarily carry out early-stage research, development and production activities are entering into agreements with key industry leaders to out-license the rights to their products, utilizing the strengths of the larger companies in terms of commercialization expertise, manufacturing, distribution and marketing capabilities and global presence.
  • Meanwhile, key players keen to secure novel and promising molecules are willing to co-operate with small players to in-license promising early-stage assets to expand their portfolios, reduce R&D risks and move ahead in the market.
  • Also, therapies have historically been manufactured in a one-size-fits-all approach for chronic diseases, among other therapy areas. Recently, a more personalized approach is being chosen by pharmaceutical companies, which are increasing the development of targeted therapies even for rare diseases.

Description

Although the pharmaceutical market is continuing to witness global growth, pharmaceutical and biotechnology companies are facing challenges due to disruptive events in the healthcare market, such as increasing costs of production and R&D, shifts in patent laws, and challenges in the economy. Companies are considering various strategies to overcome these challenges, with deal making being foremost among these as a means of boosting revenues over a short period of time.

Small companies that primarily carry out early-stage research, development and production activities are entering into agreements with key industry leaders to out-license the rights to their products, utilizing the strengths of the larger companies in terms of commercialization expertise, manufacturing, distribution and marketing capabilities and global presence. Additionally, many companies have successfully implemented deal-making strategies to secure extended protection for their products from generic competitors. Deal activity can help pharma companies to enhance their research and regulatory approaches, and can aid portfolio expansion and diversification, geographic expansion, entry into niche markets, commercialization, and sales.

This report analyzes the importance of deal making in the pharmaceutical and healthcare market. It covers key factors that encourage deal activity in the pharmaceutical industry, and the key strategies being implemented when companies strike deals. An overview of recent deal activity from 2010 to May 2017 is also included.

Scope

  • What deal making strategies have been used in recent years to boost R&D productivity and allow the successful commercialization of pharmaceutical products?
  • In which geographical markets and disease areas has deal activity been focused since 2010?
  • At which stage of development did deals most frequently occur, and attract the highest value?
  • How have pharma companies been using deal making to strengthen their product portfolio and bottom line?
  • What are the most significant Mergers and Acquisitions (M&As), licensing deals and partnership deals to have been announced since 2016?
  • Who are the major players in pharmaceutical deal making, and what has been their recent and key deal activity?

Reasons To Buy

  • Gain a comprehensive understanding of the most recent healthcare deal trends.
  • Understand the most significant M&As, licensing deals and partnerships to have occurred in recent years.
  • Comprehensively analyze the trends of deal activity from 2010 to May 2017, with respect to aggregate deal value, geography, and the therapy area and stage of development of the products involved.
  • Understand the deal-making strategies that have been historically implemented by companies, and identify the most suitable strategies for boosting R&D portfolio and bottom line performance.
  • Identify the key deal terminations that have occurred in recent years, and understand their effect.

Let’s get started...

Broker Rating Markets Available Fees Open an Account
Kawase Logo
1 Star2 Stars3 Stars4 Stars5 Stars
Rating 3.60 /5
(15 votes cast)
Loading...
Shares, Indices, Forex and Oil Spread From 0.1 and 0.2% Commission Visit Website
Plus500 Logo
1 Star2 Stars3 Stars4 Stars5 Stars
Rating 4.48 /5
(452 votes cast)
Loading...
Stocks, Commodities, Indices and Forex. Zero commissions. No monthly fees. $10 USD fee for unused account for a period of three months. Visit Website
MaxFx Logo
1 Star2 Stars3 Stars4 Stars5 Stars
Rating 4.70 /5
(89 votes cast)
Loading...
Indices, Forex, Metals, Shares From 0.1 Raw Interbank Spread Visit Website

Related Articles

29.06.2015.

Greece to Dominate Sentiment


03.08.2012.

FX Trade


Risk warning: Your capital may be at risk. CFD trading is suitable for experienced traders and not beginners.